These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Medical therapy of pulmonary hypertension. The prostacyclins. Galié N; Manes A; Branzi A Clin Chest Med; 2001 Sep; 22(3):529-37, x. PubMed ID: 11590846 [TBL] [Abstract][Full Text] [Related]
26. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721 [TBL] [Abstract][Full Text] [Related]
27. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. Voswinckel R; Enke B; Reichenberger F; Kohstall M; Kreckel A; Krick S; Gall H; Gessler T; Schmehl T; Ghofrani HA; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Olschewski H J Am Coll Cardiol; 2006 Oct; 48(8):1672-81. PubMed ID: 17045906 [TBL] [Abstract][Full Text] [Related]
28. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. Clapp LH; Gurung R Prostaglandins Other Lipid Mediat; 2015 Jul; 120():56-71. PubMed ID: 25917921 [TBL] [Abstract][Full Text] [Related]
29. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. McLaughlin VV; Palevsky HI Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307 [TBL] [Abstract][Full Text] [Related]
30. Emerging medical therapies for pulmonary arterial hypertension. Galiè N; Manes A; Branzi A Prog Cardiovasc Dis; 2002; 45(3):213-24. PubMed ID: 12525997 [TBL] [Abstract][Full Text] [Related]
31. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. Sandifer BL; Brigham KL; Lawrence EC; Mottola D; Cuppels C; Parker RE J Appl Physiol (1985); 2005 Dec; 99(6):2363-8. PubMed ID: 16141385 [TBL] [Abstract][Full Text] [Related]
32. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
33. Different efficacy of inhaled and oral medications in pulmonary hypertension. AbuHalimeh BJ; Parambil JG; Tonelli AR Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831 [TBL] [Abstract][Full Text] [Related]
35. [Progress in pharmacotherapy of pulmonary arterial hypertension in children]. Yu YP; Huang XM Zhongguo Dang Dai Er Ke Za Zhi; 2012 Mar; 14(3):236-40. PubMed ID: 22433419 [TBL] [Abstract][Full Text] [Related]
36. Treatment of pulmonary arterial hypertension in pregnancy. Huang S; DeSantis ER Am J Health Syst Pharm; 2007 Sep; 64(18):1922-6. PubMed ID: 17823103 [TBL] [Abstract][Full Text] [Related]
37. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Waxman AB; Zamanian RT Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683 [TBL] [Abstract][Full Text] [Related]
38. Prostanoids for pulmonary arterial hypertension. Galiè N; Manes A; Branzi A Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012 [TBL] [Abstract][Full Text] [Related]
39. Treatment of pulmonary arterial hypertension. Humbert M; Sitbon O; Simonneau G N Engl J Med; 2004 Sep; 351(14):1425-36. PubMed ID: 15459304 [No Abstract] [Full Text] [Related]